Evidence map›Paper›PMID 38910428›Full record

ArticleCurrent protein & peptide science2024

Evaluation of Novel HLM Peptide Activity and Toxicity against Planktonic and Biofilm Bacteria: Comparison to Standard Antibiotics.

Majed M Masadeh, Haneen Alshogran, Mohammad Alsaggar, Salsabeel H Sabi, Enaam M Al Momany, Majd M Masadeh, Nasr Alrabadi, Karem H Alzoubi

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Current protein & peptide science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Majed M MasadehDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Haneen AlshogranDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Mohammad AlsaggarDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Salsabeel H SabiDepartment of Biology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Enaam M Al MomanyDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, P.O. box 330127, Zarqa 13133, Jordan.
Majd M MasadehDiscipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, 11800, Penang, Malaysia.
Nasr AlrabadiDepartment of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Karem H AlzoubiDepartment of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.

Funding

Jordan University of Science and Technology
6 · The paper itself

Abstract

backgroundAntibiotic resistance is one of the main concerns of public health, and the whole world is trying to overcome such a challenge by finding novel therapeutic modalities and approaches. This study has applied the sequence hybridization approach to the original sequence of two cathelicidin natural parent peptides (BMAP-28 and LL-37) to design a novel HLM peptide with broad antimicrobial activity.

methodsThe physicochemical characteristics of the newly designed peptide were determined. As well, the new peptide's antimicrobial activity (Minimum Inhibitory Concentration (MIC), Minimum Bacterial Eradication Concentration (MBEC), and antibiofilm activity) was tested on two control (

resultsThe MIC values for the HLM peptide were obtained as 20, 10, 20, and 20 μM, respectively. Also, the results showed no hemolysis action, with low to slightly moderate toxicity action against mammalian cells, with an IC

conclusionThe results indicated that HLM-hybridized peptide displayed a broad-spectrum activity toward different bacterial strains in planktonic and biofilm forms. It showed synergistic or additive antimicrobial activity upon combining with commercially available different antibiotics.

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesBiofilmsMicrobial Sensitivity TestsAnimalsCathelicidinsChlorocebus aethiopsDrug SynergismEscherichia coliHemolysisHumansMethicillin-Resistant Staphylococcus aureusPlanktonProteinsStaphylococcus aureusVero CellsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBMAP-28CathelicidinsProteinsAntimicrobial activitybiofilmHLM.MBECpeptidestoxicity

Identifiers

PMID38910428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.